Navigation Links
China Medical Technologies Reports First Quarter Financial Results
Date:8/28/2007

1,569) (206)

Amortization

of convertible

notes issuance

cost -- (2,064) (2,043) (268)

Income before

tax 50,524 92,919 59,618 7,832

Income tax

expense (4,606) (9,194) (7,927) (1,041)

Net income 45,918 83,725 51,691 6,791

Earnings per

ADS - basic 1.68 3.20 1.97 0.26

- diluted (2) 1.68 3.11 1.96 0.26

Weighted

average

number of

ADS

- basic 27,360,000 26,196,308 26,196,308 26,196,308

- diluted(2) 27,385,701 30,882,901 26,317,214 26,317,214

Notes:

(1) Revenues, net

- ECLIA 42,810 65,879 79,051 10,385

- FISH -- -- 14,442 1,897

- HIFU 48,138 97,224 57,997 7,619

90,948 163,103 151,490 19,901

(2) In computing diluted EPS for the three months ended March 31, 2007,

interest expense and amortization in connection with convertible notes

were added back to net income before dividing by the diluted number of

ADS because potential shares from the conversion of convertible notes

were included. For the three months ended June 30, 2007, the total

number of potential shares to be converted pursuant to the conversion

of convertible notes was not included in the computation of diluted

EPS because to do so would have been anti-dilutive.

China Medical Technologies, Inc.

Reconciliations of Non-GAAP Adjusted Net Income to GAAP Net Income


'/>"/>

SOURCE China Medical Technologies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. How do you level the playing field with China?
2. Medical College receives $377K to study brain disease
3. Barriers will not stop convergence of medical technologies
4. Medical College team creates website for tracking flu
5. Biomedical engineering conference invites manufacturers
6. Visions: Wade offers straight talk on e-medical records
7. Merge unveils updated medical imaging software
8. Medical College receives $1.4M cancer grant
9. Medical technology firm lands $100K federal grant
10. Doyle outlines spending for Medical College, UWM
11. And the winners in medical design are
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)...   Y-Prime, Inc ., announced today that ... in Philadelphia , June 15-18 ... allows influential decision makers from the Biotech industry ... emerging technologies such as YPrime. "Our ... implementation and management of Interactive Response Technology (IRT) ...
(Date:6/2/2015)... MARLBOROUGH, Mass. , June 2, 2015 ... ), a biotechnology company focused on discovering ... areas of dermatology and ophthalmology, today announced that ... Development Officer, will present at the 23 ... This six-day world congress will include in-depth ...
(Date:6/2/2015)... MGB Biopharma at the ... MGB Biopharma, a biopharmaceutical company developing ... the major global problem of antibiotic resistance - ... (IV) formulation of MGB-BP-3, designed for the treatment of ... The intravenous formulation of MGB-BP-3 is currently in ...
(Date:6/1/2015)... DUBLIN , June 1, 2015 /PRNewswire/ ... http://www.researchandmarkets.com/research/jpslnm/oxidative_stress ) has announced the addition of ... Product (Consumables, Instruments, Services), Test Type (Indirect, ... Chromatography, Flow Cytometry), End Users - Global ... offering.      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ...
Breaking Biology Technology:YPrime at BIO Exhibition in Philadelphia and DIA in Washington DC during the month of June 2RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology 2RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology 3RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology 4MGB Biopharma Succeeds in Developing an IV Formulation of MGB-BP-3 for the Treatment of Systemic Susceptible and Resistant Gram-Positive Hospital-Acquired Infections 2MGB Biopharma Succeeds in Developing an IV Formulation of MGB-BP-3 for the Treatment of Systemic Susceptible and Resistant Gram-Positive Hospital-Acquired Infections 3Oxidative Stress Assay Market 2015 - Global Forecast to 2020 2
... , , NEW YORK, Aug. 5 ... a biopharmaceutical company focused on the acquisition, development and ... treatment of life-threatening diseases, including renal disease and cancer ... quarter ended June 30, 2009. , , ...
... , , , SADDLE ... a leading provider of sales and marketing support to U.S. pharmaceutical companies, ... Recent highlights include: , , , Four ... Signed agreement with The Medical Affairs Company (TMAC(R)) to enhance ...
... , SAN DIEGO, Aug. 5 Orexigen(R) Therapeutics, Inc. ... of obesity, today announced that the Company will be speaking at the ... follows: , , ... a.m. Eastern, Location: InterContinental Boston, London Room, ...
Cached Biology Technology:Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results 2Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results 3Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results 4Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results 5Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results 6PDI Reports 2009 Second Quarter Financial Results 2PDI Reports 2009 Second Quarter Financial Results 3PDI Reports 2009 Second Quarter Financial Results 4PDI Reports 2009 Second Quarter Financial Results 5PDI Reports 2009 Second Quarter Financial Results 6PDI Reports 2009 Second Quarter Financial Results 7PDI Reports 2009 Second Quarter Financial Results 8PDI Reports 2009 Second Quarter Financial Results 9
(Date:5/25/2015)... SYDNEY , May 25, 2015  Australia,s market ... inception stage, although 2014 saw the advent of several ... on 24 April 2015 is expected to ignite interest ... devices in Australia . This in ... the industry and drive new partnerships amongst vendors and ...
(Date:5/22/2015)... May 22, 2015 According to ... Solution (2D, 3D, Thermal, Emotion, Forensic), by Software (Middleware, Databases), ... and Utilities, Consumer and Home) - Global Forecast to ... from $2.77 Billion in 2015 to $6.19 Billion by ... Browse 79 market data Tables and   43 Figures ...
(Date:5/21/2015)... 2015 The Sync Project™ , a ... health, today announced a collaborative partnership with Berklee,s ... center on collaboration on original research, joint course development ... the collaboration, The Sync Project and BerkleeICE are exploring ... in the 2015-2016 academic year.  The ...
Breaking Biology News(10 mins):Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 2Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 3Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 4Facial Recognition Market Worth $6.19 Billion by 2020 2Facial Recognition Market Worth $6.19 Billion by 2020 3The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 3
... pre-Columbian Amazonian populations settled in large numbers across Amazonia ... take to be ‘natural.' , This view has become ... in a recent paper from Dr. Mark Bush of ... research may rekindle a debate has major implications for ...
... an ancient wheat variety have led to a major advance ... of papers published in the journal Plant Physiology researchers describe ... genes work by excluding salt from different parts of the ... The discovery of the two genes is the subject of ...
... believe they have discovered by chance a new ... of the esophagus, liver and skin. Early work ... proliferator-activated receptor-gamma (PPARgamma) inhibitors may have an unexpected ... the journal International Cancer Research. Furthermore, the new ...
Cached Biology News:Paper challenges 1491 Amazonian population theories 2Paper challenges 1491 Amazonian population theories 3Paper challenges 1491 Amazonian population theories 4Ancient genes used to produce salt-tolerant wheat 2Gut research yields new anti-cancer approach 2Gut research yields new anti-cancer approach 3Gut research yields new anti-cancer approach 4
MAb to Hu-IFN-Gamma RC2 (CD118), NON-Neutralizing, Clone MMHGR-2 Binds to but does not neutralize human interferon gamma receptor...
Recombinant Rat CINC-2 beta, CF...
SHEEP ANTI FLECAINIDE...
RAT ANTI MOUSE F4/80 ANTIGEN:BIOTIN Immunogen: Thioglycollate stimulated peritoneal macrophages from C57/BL mice...
Biology Products: